Category: Unknown Primary (CUP)
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that it will present new findings to advance and reinvent cancer care at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 31 to June 4, 2019, at the McCormick Convention Center in Chicago.
Caris Life Sciences Announces Presentations at ESMO 2017 Highlighting Ability of its Tumor Molecular Profiling to Develop Therapeutic Strategies
Comprehensive Genomic Profiling Plus of DNA, RNA and Proteins Enables Personalized Therapy Decisions across Immunotherapy, Targeted Therapy and Chemotherapy IRVING, Texas, Sept. 7, 2017 – Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced results from two studies that further validate the benefits of its … Read More
Caris Life Sciences’ Molecular Intelligence Platform Identifies Patients with MSI-High (or Mismatch Repair Deficient) Solid Tumors More Likely to Respond to Immunotherapy
Results Published in Science Demonstrate Molecular Profile of Tumor Cells Rather than Tumor Origin Can Drive Therapeutic Strategy IRVING, Texas, June 8, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today highlighted an article published in Science containing data on microsatellite instability (MSI) status … Read More
Evidence-Guided Molecular Profiling Offers New Hope for Oncologists Managing Difficult-to-Treat Cancers
AMSTERDAM, Sept. 29, 2013 — Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress (ECC 2013), which demonstrate the potential of evidence-guided molecular profiling to improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that … Read More